NCT05405660: An ongoing trial by Celldex Therapeutics
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05405660 |
|---|---|
| Title | : A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Inducible Urticaria |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 28, 2022 |
| Completion date | June 12, 2024 |
| Required reporting date | June 12, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |